Literature DB >> 2481589

Heterogeneity in the ability of IgG1 monoclonal anti-D to promote lymphocyte-mediated red cell lysis.

B M Kumpel1, K A Leader, A H Merry, A G Hadley, G D Poole, A Blancher, D Goossens, N C Hughes-Jones, B A Bradley.   

Abstract

Thirty-four IgG anti-D human monoclonal antibodies (mAb) derived from 18 donor were assessed for their ability to mediate lysis of D+ red cells by lymphocytes in antibody-dependent cell-mediated cytotoxicity assays. Cell-bound antibody was quantified and the mAb were compared at similar levels of sensitization. The majority (23/31) of IgG1 and all (3/3) IgG3 mAb were ineffective; two donors produced both lytic and non-lytic anti-D mAb. Greater sensitivity was achieved using fluid-phase antibody (as culture supernatants) in the assay than was obtained with pre-sensitized red cells. Minimum levels of 2000 anti-D molecules per cell were required for lysis using pre-sensitized cells. Partial D red cells (DIVa, DVa and DVI) were lysed by three mAb that were lytic with normal D+ cells. There was no relationship between lytic ability and Gm allotype or D epitope specificity of the antibodies. Four mAb to other blood group specificities were tested: two (anti-E and anti-G) were lytic and two (anti-c and anti-Kell) were not lytic. Possible reasons for the heterogeneity of the lytic activity by the mAb are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2481589     DOI: 10.1002/eji.1830191216

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  Germline variable region gene segment derivation of human monoclonal anti-Rh(D) antibodies. Evidence for affinity maturation by somatic hypermutation and repertoire shift.

Authors:  J M Bye; C Carter; Y Cui; B D Gorick; S Songsivilai; G Winter; N C Hughes-Jones; J D Marks
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

2.  Functional interactions of aglycosylated monoclonal anti-D with Fc gamma RI+ and Fc gamma RIII+ cells.

Authors:  K A Leader; B M Kumpel; A G Hadley; B A Bradley
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

3.  The functional activity of human monocytes passively sensitized with monoclonal anti-D suggests a novel role for Fc gamma RI in the immune destruction of blood cells.

Authors:  H L Griffiths; B M Kumpel; C J Elson; A G Hadley
Journal:  Immunology       Date:  1994-11       Impact factor: 7.397

4.  Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes.

Authors:  R G Bredius; C A Fijen; M De Haas; E J Kuijper; R S Weening; J G Van de Winkel; T A Out
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

5.  Antibody-mediated immunosuppression can result from RBC antigen loss independent of Fcγ receptors in mice.

Authors:  Amanda Mener; Seema R Patel; Connie M Arthur; Sean R Stowell
Journal:  Transfusion       Date:  2018-11-26       Impact factor: 3.157

6.  Antibody responses to the blood group antigen D in SCID mice reconstituted with human blood mononuclear cells.

Authors:  K A Leader; L M Macht; F Steers; B M Kumpel; C J Elson
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

7.  The functional activity of Fc gamma RII and Fc gamma RIII on subsets of human lymphocytes.

Authors:  A G Hadley; B Zupanska; B M Kumpel; K A Leader
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

8.  Glycosylation and functional activity of anti-D secreted by two human lymphoblastoid cell lines.

Authors:  D Cant; J Barford; C Harbour; A Fletcher; N Packer; A Gooley
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

9.  Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of Fcgamma RIIIa (CD16).

Authors:  B M Kumpel; M De Haas; H R Koene; J G J Van De Winkel; M J Goodrick
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

10.  Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy.

Authors:  Belinda M Kumpel; Radka Saldova; Carolien A M Koeleman; Jodie L Abrahams; Agnes Hipgrave Ederveen; Kathryn L Armour; Natalia I Olovnikova; Gestur Vidarsson; Rick Kapur; Pauline M Rudd; Manfred Wuhrer
Journal:  Sci Rep       Date:  2020-01-30       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.